Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
Clinical and Translational Oncology · 28.03.2024 · 26 (9) · 2217-2226
DOI: 10.1007/s12094-024-03440-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Translational Oncology, online erschienen am 28.03.2024. Verfasst von Alejandro Falcón González und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Virgen del Rocío, 41013, Seville, Spain. afalconglez@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche España.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuzumab and chemotherapy (CT) in early-stage HER2-positive BC.
Methods
A retrospective, multicentre study was conducted on patients diagnosed with HER2-positive early BC treated with neoadjuvant pertuzumab and trastuzumab plus CT at 13 Spanish sites. The primary endpoint was pathological complete response (pCR).
Results
A total of 310 patients were included. Pertuzumab and trastuzumab were combined with anthracyclines and taxanes, carboplatin and docetaxel, and taxane-based CT in 77.1%, 16.5%, and 6.5% of patients, respectively. Overall, the pCR rate was 62.2%. The pCR was higher amongst patients with hormone receptor-negative tumours and with tumours expressing higher levels of Ki-67 (> 20%). After postoperative adjuvant treatment, 13.9% of patients relapsed. Those patients who did not achieve pCR, with tumours at advanced stages (III), and with node-positive disease were more likely to experience distant relapse. Median overall survival (OS) and distant disease-free survival (D-DFS) were not reached at the study end. The estimated mean OS and D-DFS times were 7.5 (95% CI 7.3–7.7) and 7.3 (95% CI 7.1–7.5) years, respectively (both were significantly longer amongst patients who achieved pCR). Grade 3–4 anti-HER2 related toxicities were reported in six (1.9%) patients.
Conclusion
Neoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Universitario Virgen del Rocío, 41013, Seville, Spain. afalconglez@gmail.com.
- Medical Oncology Department, Hospital Universitario de Canarias, 38320, Santa Cruz, Tenerife, Spain.
- Oncology Service, Complejo Hospitalario Universitario Insular Materno-Infantil, 35016, Las Palmas, Gran Canaria, Spain.
- Medical Oncology Department, Hospital Universitario de Jaén, 23009, Jaén, Spain.
- Medical Oncology Department, Hospital Universitario Virgen Macarena, 41009, Seville, Spain.
- Oncology Department, Complejo Hospitalario Torrecárdenas de Almería, 04009, Almería, Spain.
Förderung
- Roche España
Zitieren
APA
Falcón González, A., Cruz Jurado, J., Llabrés Valenti, E., Urbano Cubero, R., Álamo de la Gala, M. C., Martínez Guisado, M. A., Álvarez Ambite, R., Rodríguez González, C. J., Amérigo Góngora, M., Rodríguez Pérez, L., López Álvarez, P., Sánchez Rovira, P., González Flores, E., Henao Carrasco, F., Bayo Calero, J., Valero Arbizu, M., Quílez Cutillas, A., Salvador Boffil, J., Rubio Pérez, E., & Ruiz-Borrego, M. (2024). Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study. Clinical and Translational Oncology, 26(9), 2217-2226. https://doi.org/10.1007/s12094-024-03440-5
Vancouver
Falcón González A, Cruz Jurado J, Llabrés Valenti E, Urbano Cubero R, Álamo de la Gala MC, Martínez Guisado MA, et al. Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study. Clinical and Translational Oncology. 2024;26(9):2217-2226. doi:10.1007/s12094-024-03440-5
BibTeX
@article{FalcnGonzlez2024,
author = {Falcón González, Alejandro and Cruz Jurado, Josefina and Llabrés Valenti, Elisenda and Urbano Cubero, Rocío and Álamo de la Gala, Maria Carmen and Martínez Guisado, María Antonia and Álvarez Ambite, Rocío and Rodríguez González, Carlos José and Amérigo Góngora, Marta and Rodríguez Pérez, Lourdes and López Álvarez, Pilar and Sánchez Rovira, Pedro and González Flores, Encarnación and Henao Carrasco, Fernando and Bayo Calero, Juan and Valero Arbizu, María and Quílez Cutillas, Alicia and Salvador Boffil, Javier and Rubio Pérez, Eloísa and Ruiz-Borrego, Manuel},
title = {Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study},
journal = {Clinical and Translational Oncology},
year = {2024},
volume = {26},
number = {9},
pages = {2217--2226},
doi = {10.1007/s12094-024-03440-5}
}
EUVIMED